Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs. - RIIP - Réseau International des Instituts Pasteur Access content directly
Journal Articles Future Medicinal Chemistry Year : 2013

Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs.

Abstract

Leishmaniasis is a neglected disease that kills 60,000 people worldwide, and which is caused by the protozoa Leishmania. The enzymes of the trypanothione pathway: trypanothione synthetase-amidase, trypanothione reductase (TR) and tryparedoxin-dependent peroxidase are absent in human hosts, and are essential for parasite survival and druggable. The most promising target is trypanothione synthetase-amidase, which has been also chemically validated. However, the structural data presented in this review show that TR also should be considered as a good target. Indeed, it is strongly inhibited by silver- and gold-containing compounds, which are active against Leishmania parasites and can be used for the development of novel antileishmanial agents. Moreover, TR trypanothione-binding site is not featureless but contains a sub-pocket where inhibitors bind, potentially useful for the design of new lead compounds.
No file

Dates and versions

pasteur-01023953 , version 1 (15-07-2014)

Identifiers

Cite

Gianni Colotti, Paola Baiocco, Annarita Fiorillo, Alberto Boffi, Elena Poser, et al.. Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs.. Future Medicinal Chemistry, 2013, 5 (15), pp.1861-75. ⟨10.4155/fmc.13.146⟩. ⟨pasteur-01023953⟩

Collections

RIIP RIIP_FCB
16 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More